- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06285201
Study of Felzartamab in Healthy Adult Subjects
April 11, 2024 updated by: TJ Biopharma Co., Ltd.
A Phase 1 Clinical Study to Evaluate the Pharmacokinetic Comparability, Safety, Tolerability, and Immunogenicity of Felzartamab for Injection in Healthy Male Adult Subjects in China (Randomized, Double-blind, Crossover Design)
A Phase 1 Clinical Study to Evaluate the Pharmacokinetic Comparability, Safety, Tolerability, and Immunogenicity of Felzartamab for Injection Pre- and Post-changes of Process in Healthy Male Adult Subjects in China (Randomized, Double-blind, Single-dose, Two-formulation, Two-sequence, Two-period Crossover Design)
Study Overview
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaojiao Li, Doctor
- Phone Number: +8613514314089
- Email: xingxingsuo123456@126.com
Study Locations
-
-
Changchun
-
Jilin, Changchun, China
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Xiaojiao Li, Doctor
- Phone Number: +8613514314089
- Email: xingxingsuo123456@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male subjects aged ≥ 18 years and ≤ 50 years when signing the ICF.
- Weight ≥ 50 kg and ≤ 80 kg, with a BMI ≥ 19.0 and ≤ 28.0 kg/m2 (inclusive).
- The study doctor determines that the overall health status of the subject is good (normal or abnormal but not clinically significant) based on the subject's medical history, physical examinations, vital signs, ECG, and laboratory test results.
- Subjects who are voluntarily participate in the study, and can understand and sign the ICF.
- Subjects (including their partners) who have no plans for pregnancy or sperm donation during the study and within 6 months after the last dose, and voluntarily use effective contraceptive measures. Specific contraceptive measures are described in Appendix 4.
Exclusion Criteria:
- Subjects with diseases that may affect his safety or the results of the study, including but not limited to cardiovascular, respiratory, endocrine, metabolic, renal, hepatic, gastrointestinal, dermatological, infectious, malignant tumors, hematological, skeletal, genitourinary, neurological/psychiatric diseases, and are clinically significant in the opinion of the investigator.
- Subjects who have had acute, chronic, or potential infectious diseases within 1 month pre-dose.
- Subjects with known immune system diseases (such as autoimmune diseases or immunodeficiency diseases), including but not limited to autoimmune hemolytic anemia, etc.
- Subjects who have had a single episode of herpes zoster (shingles) involving the skin or central nervous system within the 6 months pre-dose.
- Subjects who currently have or have a history of multiple episodes of herpes zoster involving the skin or central nervous system.
- Subjects with chronic diarrhea or enteritis within 1 year pre-dose.
- Subjects with positive result for blood group antibody screening (IAT).
- Subjects who have received monoclonal antibodies, cell therapies within 6 months pre-dose, or have previously received daratumumab or similar drugs, or drugs targeting CD38.
- Subjects who have taken any medicine, including prescription drugs, over-the-counter drugs, and herbal medicine, within two weeks pre-dose.
- Subjects who are suspected or confirmed to be allergic to multiple drugs or foods, including drugs or drug excipients in this clinical study.
- Subjects who have a history of fear of needles or blood, or have difficulty with venous blood collection (have a history of difficulty with blood collection or have corresponding symptoms and signs, and cannot tolerate venous puncture).
- Subjects with the history of blood donation or blood loss of ≥ 200mL in total within 3 months pre-dose;
- Subjects who have participated in any other clinical studies of investigation drug or medical device within the 3 months pre-dose (or 5 half-lives for investigation drugs with so long half-life that the duration of its 5 half- lives is > 3 months).
- Subjects who have undergone major surgery within the last 3 months prior to signing the ICF.
- Subjects who are positive for Hepatitis B (positive for HBsAg or HBcAb and HBV-DNA levels of ≥ 500 cps/mL [or HBV-DNA ≥ 100 IU/mL]), HCV antibodies, HIV antibodies, and anti-TP antibodies.
- Smokers who have smoked more than 5 cigarettes per day in the 3 months prior to the study or who are unable to stop using any tobacco products during the study.
- Subjects who have received attenuated or live viral vaccines (such as Bacille Calmette-Guérin [BCG]) or viral vector vaccines within 12 months before the first dose of investigation drug, or plan to receive within 12 months post-dose.
- Subjects who have received vaccines other than attenuated or live virus vaccines, as well as virus vector vaccines talked above, such as inactivated vaccines, recombinant subunit vaccines, etc. within the 1 month before the first dose.
- The investigator determines the subjects have any other factors that make them unsuitable to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
T-R
|
8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
8 mg/kg IV of Test drug manufactured by Patheon Italia
|
Experimental: Group B
R-T
|
8 mg/kg IV of Test drug manufactured by I-Mab Biopharma(Hangzhou)
8 mg/kg IV of Test drug manufactured by Patheon Italia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary PK Endpoint
Time Frame: 36 days after dosing
|
AUC0-∞
|
36 days after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Xiaojiao Li, Doctor, The First Hospital of Jilin University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 27, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
February 22, 2024
First Submitted That Met QC Criteria
February 22, 2024
First Posted (Actual)
February 29, 2024
Study Record Updates
Last Update Posted (Estimated)
April 15, 2024
Last Update Submitted That Met QC Criteria
April 11, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- TJ202001BE104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on T
-
Biotronik SE & Co. KGCompletedHeart Failure | BradycardiaDenmark, Hong Kong, Austria, Germany, Belgium
-
University of California, BerkeleyUniversity of Nevada, Reno; World Bank; L'Office National de Nutrition, MadagascarRecruitingEarly Childhood DevelopmentMadagascar
-
Biotronik SE & Co. KGCompletedVentricular Fibrillation | Ventricular TachycardiaGermany, Czech Republic
-
University of South FloridaNational Cancer Institute (NCI)RecruitingCancer | Obesity, Childhood | SurvivorshipUnited States
-
Hebei Senlang Biotechnology Inc., Ltd.RecruitingLymphoma | Multiple Myeloma | Acute Lymphoblastic LeukemiaChina
-
Xuzhou Medical UniversityNot yet recruiting
-
The First Affiliated Hospital of Soochow UniversityRecruitingRelapsed/Refractory B-cell Non-Hodgkin's LymphomaChina
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...RecruitingBreast Cancer | HER2-positive Breast Cancer | Malignant Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the LeptomeningesUnited States
-
Everett MeyerNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedLymphoma, Non-Hodgkin | Acute Myeloid Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplastic Syndromes (MDS) | Acute Lymphoblastic Leukemia (ALL) | Myeloid Leukemia, Chronic | Myeloproliferative SyndromeUnited States
-
Sorrento Therapeutics, Inc.WithdrawnBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreas Cancer | Peritoneal Carcinomatosis | Peritoneal Metastases | Carcinoembryonic AntigenUnited States